Dr. William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare ...
At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization in the European Union for Romvimza ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- An ...
Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor (TGCT) that may be made worse by surgery. TGCT is a condition where tumors form in joints of the ...
New microfluidic device improves the separation of tumor cells and clusters from malignant effusions
Researchers have unveiled a microfluidic device that significantly improves the separation of tumor cells and clusters from malignant effusions. This novel technology promises to advance the diagnosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback